Search: WFRF:(Frisk A.) >
Combining CAR T cel...
Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy
-
- Karlsson, S. C. Hannah (author)
- Uppsala universitet,Science for Life Laboratory, SciLifeLab,Klinisk immunologi
-
- Lindqvist, A. C. (author)
- Uppsala universitet,Institutionen för immunologi, genetik och patologi,Science for Life Laboratory, SciLifeLab
-
- Fransson, Moa (author)
- Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
-
show more...
-
- Paul-Wetterberg, Gabriella (author)
- Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
-
- Nilsson, Bo (author)
- Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
-
- Essand, Magnus (author)
- Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
-
- Nilsson, Kristina (author)
- Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
-
- Frisk, Per (author)
- Uppsala universitet,Pediatrik
-
- Jernberg-Wiklund, Helena (author)
- Uppsala universitet,Hematologi och immunologi,Science for Life Laboratory, SciLifeLab
-
- Loskog, S. I. A. (author)
- Uppsala universitet,Institutionen för immunologi, genetik och patologi,Science for Life Laboratory, SciLifeLab
-
show less...
-
(creator_code:org_t)
- 2013-06-21
- 2013
- English.
-
In: Cancer Gene Therapy. - : Springer Science and Business Media LLC. - 0929-1903 .- 1476-5500. ; 20:7, s. 386-393
- Related links:
-
https://www.nature.c...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- B-cell malignancies upregulate the B-cell lymphoma 2 (Bcl-2) family inhibitors of the intrinsic apoptosis pathway, making them therapy resistant. However, small-molecule inhibitors of Bcl-2 family members such as ABT-737 restore a functional apoptosis pathway in cancer cells, and its oral analog ABT-263 (Navitoclax) has entered clinical trials. Gene engineered chimeric antigen receptor (CAR) T cells also show promise in B-cell malignancy, and as they induce apoptosis via the extrinsic pathway, we hypothesized that small-molecule inhibitors of the Bcl-2 family may potentiate the efficacy of CAR T cells by engaging both apoptosis pathways. CAR T cells targeting CD19 were generated from healthy donors as well as from pre-B-ALL (precursor-B acute lymphoblastic leukemia) patients and tested together with ABT-737 to evaluate apoptosis induction in five B-cell tumor cell lines. The CAR T cells were effective even if the cell lines exhibited different apoptosis resistance profiles, as shown by analyzing the expression of apoptosis inhibitors by PCR and western blot. When combining T-cell and ABT-737 therapy simultaneously, or with ABT-737 as a presensitizer, tumor cell apoptosis was significantly increased. In conclusion, the apoptosis inducer ABT-737 enhanced the efficacy of CAR T cells and could be an interesting drug candidate to potentiate T-cell therapy.
Keyword
- ABT-737
- BH3 mimetics
- engineered T cells
- CAR
- Bcl-2
- pre-B-ALL
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database